Clinical Trials Logo

Malignant Melanoma clinical trials

View clinical trials related to Malignant Melanoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04285749 Withdrawn - Malignant Melanoma Clinical Trials

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Start date: November 6, 2020
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine whether a medication, fluvastatin, can change melanoma to a state that is less likely to metastasize or recur. Fluvastatin is experimental in this setting because it is not approved by the Food and Drug Administration (FDA) for treatment or prevention of melanoma. However, fluvastatin has been approved by the FDA for treating high cholesterol.

NCT ID: NCT04223648 Withdrawn - Malignant Melanoma Clinical Trials

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Start date: August 15, 2020
Phase: Early Phase 1
Study type: Interventional

The primary objective of this pilot study is to assess the feasibility of mobilizing PD-1+ T cells to the peripheral blood after a single treatment with tremelimumab/durvalumab in patients with treatment naïve metastatic melanoma.

NCT ID: NCT02661100 Withdrawn - Clinical trials for Non Small Cell Lung Cancer

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug. CDX-1401 is a tumor specific antigen and Poly-ICL is a Toll-like receptor agonist tumor specific antigens which when combined with Pembrolizumab may increase the tumor response to this drug.

NCT ID: NCT00963664 Withdrawn - Melanoma Clinical Trials

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether an outpatient combination of lovastatin and low-to-moderate dose interferon is effective in the treatment of patients with malignant melanoma.

NCT ID: NCT00535314 Withdrawn - Malignant Melanoma Clinical Trials

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.